Joanne Bowen

Research Interests

Cancer Therapy Chemotherapy Immunogenetics Microbial Ecology Systems Biology Cancer Biology and Clinical Oncology Neuroscience, Behaviour and Brain Health Nutrition and Metabolic Health Oral Health

Prof Joanne Bowen

Professor

School of Pharmacy and Biomedical Science

College of Health

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Professor Joanne BowenB.Hlth.Sci (Hons), PhD (Medicine), M.Phil (Clin Sci), Grad.Cert. Public Health, Grad. Cert. Online LearningProf Bowen's research focuses on mechanisms and management of cancer therapy-related toxicities, with a special interest in gastrointestinal adverse effects. She was awarded an NHMRC Australian-based Biomedical Training Fellowship (2009 – 2012) to conduct novel research aimed at discovery of peripheral blood biomarkers associated with risk of toxicity during treatment for oesophageal cancer. Her recent work has lead to development of preclinical models for testing interventions for gastrointestinal toxicity utilized by the pharmaceutical industry. She is Head of the highly active Cancer Treatment Toxicities Group which supports diverse projects across the field of supportive oncology and training of the next generation of researchers.

As Head of the Cancer Treatment & Toxicities Group (@ToxicitiesGroup for X updates) in the School of Biomedicine, I am responsible for a program of research aimed at better managing side effects of cancer therapy. Our group investigates both the underlying mechanisms and the treatment approaches to prevention of some of the most common toxicities of cancer therapies including diarrhoea, vomiting, neuroinflammation and bone loss. My particular interest is in how the gastrointestinal tract responds to exposure to chemotherapy, radiation and small molecule inhibitors used in treatment of solid tumours, and how the microbiome can influence the incidence and severity of injury. My current projects focus on establishing new interventions for mitigation of gastrointestinal side effects that target interactions between the gut microbiome and immune system at the level of the mucosal barrier. Our group members include undergraduate students, through to Honours and PhD, as well as postdoctoral researchers. We conduct research projects using cell culture and organoid models, transgenic rodents, and in patient cohorts (detailed below). Our mission is to improve cancer outcomes through personalising treatment and supportive care.

Quantitative microscopyCell adhesion protein expressionIntestinal physiology changes related to diarrhoea

Gut-brain links in treatment toxicities

Images: Techniques and pathways under investigation. Top panel - Quantitiative histology; Cell junctional protein analysis; Intestinal physiology underpinning chemotherapy symptoms. Bottom image - Links between gut toxicity and central neuroinflammation (from group postdoc, Hannah Wardill, Cancer Treat Rev 2015)

 

Research Project 1

Title: Gut microbiome composition as a predictive marker for cancer treatment outcomes

Project description: Patients with cancer are at high risk of microbiome dysbiosis (lack of bacterial diversity and/or overabundance of pathogenic species) due to frequent hospital visits, surgery, chemotherapy and radiation treatment, other medications (notably prophylactic antibiotics), changes in diet, and the presence of cancer itself. Having a diverse gut microbiota is considered protective against chemotherapy-induced infections, and pre-clinical work points to bacterial diversity as a key determinant of tumour response, gastrointestinal toxicity, and neuroinflammation. Thus the objective of this project is to explore links between microbiota, inflammatory responses, and cancer treatment outcomes. Research techniques include mouse models of cancer treated with chemotherapy, bacterial gene sequencing, and a patient trial analysing longitudinal changes in microbiome composition following different cancer therapies.

Projects available for: Honours / HDR

Location: Helen Mayo Building

Research project start: Semester 1 and 2

Special requirements: Nil

 

Research Project 2

Title: Dietary interventions for protection from chemotherapy-induced bone loss

Project description: Drugs used to treat breast cancer cause damage to normal bone structure, leading to adverse symptoms such as loss of bone mineral density and fractures in survivors. Our group is working with industry to explore different dietary interventions to prevent bone loss following treatment with the chemotherapy drug, methotrexate. This project will use breast cancer rodent cancer models treated with chemotherapy. Research techniques include histological analysis, cell death assays, immunofluorescence, real time PCR and small animal handling. 

Projects available for: Third Year / Honours / HDR

Location: Helen Mayo Building

Research project start: Semester 1 and 2

Special requirements: Nil

 

Research Project 3

Title: The CANnabinoids for CANcer Therapy (CANCAN) Trial

Project description: Medicinal cannabis is being explored as a new treatment for various side effects of cancer treatment. We are conducting a randomised controlled trial in patients with solid tumours who may benefit from a medicinal cannabis product (oral CBD and THC preparations). In addition to measures of effectiveness, the project will explore patient perceptions of the medication, patient-reported outcome measures, and pharmacology of the intervention.  

Projects available for: HDR (PhD and M.Phil)

Location: Helen Mayo Building

Research project start: Semester 1 and 2

Special requirements: Nil

Date Position Institution name
2021 - ongoing Professor University of Adelaide
2017 - 2021 Associate Professor University of Adelaide

Date Type Title Institution Name Country Amount
2021 Teaching Award Stephen Cole the Elder Award for Excellence in Supervisory Practice University of Adelaide Australia -
2016 Award Telstra Women's Business Public Sector and Academia Award - - -
2014 Award MASCC Young Investigator Award - - -
2009 Award SA Young Tall Poppy Science Award Australian Institute of Policy and Science - -
2009 Fellowship NHMRC Australian-based biomedical research fellowship University of Adelaide Australia -
2008 Award MASCC Young Investigator Award - - -
2007 Award MASCC Young Investigator Award - - -
2006 Award MASCC Young Investigator of the Year - - -
2003 Scholarship Royal Adelaide Hospital Research Committee Dawes Postgraduate Research Scholarship - - -

Date Institution name Country Title
2010 - 2012 University of Adelaide Australia M.Phil (Clin Sci)
2002 - 2006 University of Adelaide Australia PhD
1997 - 2001 University of Adelaide Australia B. Hlth.Sci (Hons)

Date Title Institution name Country
— Grad. Cert. Online Learning (Higher Education) University of Adelaide Australia
— Grad. Cert. Public Health Charles Darwin University Australia

Year Citation
2025 Li, A., Costello, S. P., Bryant, R. V., Haylock-Jacobs, S., Haifer, C., Lee, C., . . . Wardill, H. R. (2025). A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME study. BMC Cancer, 25(1), 656-1-656-8.
DOI Scopus1 WoS1
2025 Sharin, R. N. F. S. R., Khan, J., Ibahim, M. J., Bowen, J., & Zain, W. N. I. W. M. (2025). Lapatinib modulates Caco-2 intestinal monolayer permeability through ErbB1 inhibition-mediated tight junction alteration. Asia-Pacific Journal of Molecular Biology and Biotechnology, 33(2), 8-23.
DOI
2025 Morcom, C. R., Williams, C. M. D., Al Qadami, G., Vieyra, C. P., Del Fabbro, E., Naito, T., . . . Wardill, H. R. (2025). Biological mechanisms underpinning nutritional and health-related consequences of mucositis in head and neck cancer-a review. Oral Oncology, 168(107548), 1-9.
DOI
2025 Bellas, O. M., Cao, K., Bowen, J., Smid, S., Shakib, S., Crawford, G. B., . . . Wardill, H. R. (2025). Medicinal CANnabis (CBD/THC) to prevent the symptoms and side effects of chemotherapy in people with advanced CANcer (CANCAN): protocol for a phase II, randomised, double-blind, placebo-controlled trial. BMJ Open, 15(3), e089336-1-e089336-10.
DOI Scopus1 Europe PMC1
2025 Vieyra, C. P., Quinn, M. J., Bateman, E. H., Wardill, H. R., & Bowen, J. M. (2025). Blautia luti reduces neratinib-induced diarrhea in a rat model.. Support Care Cancer, 33(11), 948.
DOI
2024 Abdalla-Aslan, R., Bonomo, P., Keefe, D., Blijlevens, N., Cao, K., Cheung, Y. T., . . . Nagano, C. (2024). Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study. eClinicalMedicine, 73(102675), 102675-1-102675-12.
DOI Scopus8 WoS9 Europe PMC7
2024 Dikeocha, I. J., Wardill, H. R., Coller, J. K., & Bowen, J. M. (2024). Dietary interventions and tumor response to chemotherapy in breast cancer: A comprehensive review of preclinical and clinical data. Clinical Nutrition Espen, 63, 462-475.
DOI Scopus1 WoS1 Europe PMC1
2024 Nguyen, T. P. M., Woods, S. L., Secombe, K. R., Tang, S., Elz, A. S., Ayton, S., . . . Bowen, J. M. (2024). Ferroptosis - a potential feature underlying neratinib-induced colonic epithelial injury. Cancer Chemotherapy and Pharmacology, 94(4), 493-505.
DOI Scopus1 WoS1 Europe PMC1
2024 Bowen, J., Braga, S., Zotto, V. D., Finnie, J., DiPrimeo, D., Cooke, B., . . . Di Palma, J. A. (2024). Preclinical and clinical evaluation through serial colonoscopic evaluation of neratinib-induced diarrhea in HER2-positive breast cancer-A pilot study.. Physiological Reports, 12(16), e70008-1-e70008-12.
DOI Scopus3 WoS2 Europe PMC3
2024 Chan, R. J., Knowles, R., Ashbury, F. D., Bowen, J., Chan, A., Chin, M., . . . Lustberg, M. (2024). Supportive care 2030 movement: towards unifying ambitions for global excellence in supportive cancer care—an international Delphi study. EClinicalMedicine, 76, 102825-1-102825-12.
DOI Scopus13 WoS12 Europe PMC8
2024 Cross, C. B., Bowen, J. M., Davies, M. R., & Wardill, H. R. (2024). What lurks beneath the symptom? Why more basic scientists are needed in cancer supportive care and survivorship research. Supportive Care in Cancer, 32(10), 691-1-691-3.
DOI
2024 White, C., Wardill, H., Paul, C., Price, T., Karapetis, C., Nalder, M., . . . Scott, R. J. (2024). DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol. BMC cancer, 24(1), 1369.
DOI Scopus2 WoS2 Europe PMC2
2024 Cross, C., Davies, M., Bateman, E., Crame, E., Joyce, P., Wignall, A., . . . Bowen, J. (2024). Fibre-rich diet attenuates chemotherapy-related neuroinflammation in mice. Brain, Behavior, and Immunity, 115, 13-25.
DOI Scopus12 WoS12 Europe PMC7
2023 Wardill, H. R., Wooley, L. T., Bellas, O. M., Cao, K., Cross, C. B., van Dyk, M., . . . Price, T. J. (2023). Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges. British Journal of Cancer, 130(1), 19-30.
DOI Scopus4 WoS3 Europe PMC4
2023 Bowen, J., & Cross, C. (2023). The Role of the Innate Immune Response in Oral Mucositis Pathogenesis. International Journal of Molecular Sciences, 24(22), 16314-1-16314-14.
DOI Scopus11 WoS11 Europe PMC7
2023 Li, A., Bowen, J. M., Ball, I. A., Wilson, S., Yong, A., Yeung, D. T., . . . Wardill, H. R. (2023). Autologous Faecal Microbiota Transplantation to Improve Outcomes of Haematopoietic Stem Cell Transplantation: Results of a Single-Centre Feasibility Study. Biomedicines, 11(12), 1-9.
DOI Scopus2 WoS2 Europe PMC1
2023 Al-Qadami, G., Bowen, J., Van Sebille, Y., Secombe, K., Dorraki, M., Verjans, J., . . . Le, H. (2023). Baseline gut microbiota composition is associated with oral mucositis and tumour recurrence in patients with head and neck cancer: a pilot study. Supportive Care in Cancer, 31(1), 98-1-98-14.
DOI Scopus25 WoS24 Europe PMC22
2023 Korver, S. K., Bowen, J. M., Gibson, R. J., Ball, I. A., Secombe, K. R., Wain, T. J., . . . Coller, J. K. (2023). Advanced statistics identifcation of participant and treatment predictors associated with severe adverse efects induced by fuoropyrimidine‑based chemotherapy. Cancer Chemother Pharmacol, 91(6), 507-521.
DOI Scopus3 WoS3 Europe PMC3
2023 Wardill, H. R., Da Silva Ferreira, A. R., Kumar, H., Bateman, E. H., Cross, C. B., Bowen, J. M., . . . Tissing, W. J. E. (2023). Whey-based diet containing medium chain triglycerides modulates the gut microbiota and protects the intestinal mucosa from chemotherapy while maintaining therapy efficacy.. Cell Death and Disease, 14(5), 338-1-338-11.
DOI Scopus10 WoS10 Europe PMC7
2023 Maddern, A. S., Coller, J. K., Bowen, J. M., & Gibson, R. J. (2023). The Association between the Gut Microbiome and Development and Progression of Cancer Treatment Adverse Effects. Cancers, 15(17), 4301-1-4301-22.
DOI Scopus10 WoS11 Europe PMC7
2023 Crame, E. E., Nourmohammadi, S., Wardill, H. R., Coller, J. K., & Bowen, J. M. (2023). Contribution of TLR4 to colorectal tumor microenvironment, etiology and prognosis. Journal of Cancer Research and Clinical Oncology, 149(7), 3009-3021.
DOI Scopus5 WoS4 Europe PMC3
2023 Tam, J. S. Y., Coller, J. K., Prestidge, C. A., & Bowen, J. M. (2023). Investigation of TLR4 Antagonists for Prevention of Intestinal Inflammation. Inflammation, 46(1), 103-114.
DOI Scopus12 WoS12 Europe PMC7
2022 Tam, J. S. Y., Crame, E. E., Elz, A. S., Coller, J. K., Wignall, A., Prestidge, C. A., & Bowen, J. M. (2022). Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicity. Cancer Chemotherapy and Pharmacology, 90(3), 267-278.
DOI Scopus5 WoS4 Europe PMC5
2022 Harata-Lee, Y., Qu, Z., Bateman, E., Xiao, X., Keller, M. D., Bowen, J., . . . Adelson, D. L. (2022). Compound Kushen injection reduces severity of radiation-induced gastrointestinal mucositis in rats. Frontiers in Oncology, 12, 929735-1-929735-11.
DOI Scopus10 WoS8 Europe PMC7
2022 Al-Qadami, G. H., Secombe, K. R., Subramaniam, C. B., Wardill, H. R., & Bowen, J. M. (2022). Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities. Microorganisms, 10(10), 2048-1-2048-25.
DOI Scopus103 WoS100 Europe PMC87
2022 Subramaniam, C. B., Wardill, H. R., Davies, M. R., Heng, V., Gladman, M. A., & Bowen, J. M. (2022). 5-Fluorouracil Induces an Acute Reduction in Neurogenesis and Persistent Neuroinflammation in a Mouse Model of the Neuropsychological Complications of Chemotherapy. Molecular Neurobiology, 60(3), 1408-1424.
DOI Scopus7 WoS5 Europe PMC5
2022 Tam, J. S. Y., Pei, J. V., Coller, J. K., Prestidge, C. A., & Bowen, J. M. (2022). Structural insight and analysis of TLR4 interactions with IAXO-102, TAK-242 and SN-38: an in silico approach.. In silico pharmacology, 11(1), 1-1-1-9.
DOI Europe PMC2
2022 Elz, A. S., Trevaskis, N. L., Porter, C. J. H., Bowen, J. M., & Prestidge, C. A. (2022). Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport. Journal of Controlled Release, 341, 676-701.
DOI Scopus44 WoS38 Europe PMC27
2022 Bowen, J., & Wardill, H. (2022). The science of mucositis. Supportive Care in Cancer, 30(4), 2915-2917.
DOI Scopus4 WoS2 Europe PMC1
2022 Al-Qadami, G., Van Sebille, Y., Bowen, J., & Wardill, H. (2022). Oral-Gut Microbiome Axis in the Pathogenesis of Cancer Treatment-Induced Oral Mucositis.. Frontiers in Oral Health, 3, 881949-1-881949-10.
DOI Scopus31 WoS30 Europe PMC23
2022 Al-Qadami, G., Verma, G., Van Sebille, Y., Le, H., Hewson, I., Bateman, E., . . . Bowen, J. (2022). Antibiotic-Induced Gut Microbiota Depletion Accelerates the Recovery of Radiation-Induced Oral Mucositis in Rats.. International Journal of Radiation: Oncology- Biology- Physics, 113(4), 845-858.
DOI Scopus15 WoS16 Europe PMC15
2022 Raja Sharin, R. N. F. S., Khan, J., Ibahim, M. J., Muhamad, M., Bowen, J., & Wan Mohamad Zain, W. N. I. (2022). Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review. BioMed Research International, 2022(1), 4165808-1-4165808-13.
DOI Scopus7 WoS6 Europe PMC2
2022 Secombe, K. R., Crame, E. E., Tam, S. Y. J., Wardill, H. R., Gibson, R. J., Coller, J. K., & Bowen, J. M. (2022). Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatment.. Cancer Chemotherapy and Pharmacology, 89(2), 275-281.
DOI Scopus8 WoS8 Europe PMC7
2022 Secombe, K. R., Ball, I. A., Wignall, A. D., Bateman, E., Keefe, D. M., & Bowen, J. M. (2022). Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats. Neoplasia, 30(article no. 100806), 100806-1-100806-10.
DOI Scopus13 WoS13 Europe PMC13
2021 Secombe, K. R., Al-Qadami, G. H., Subramaniam, C. B., Bowen, J. M., Scott, J., Van Sebille, Y. Z. A., . . . Wardill, H. R. (2021). Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols. Gut Microbes, 13(1), 1979878-1-1979878-15.
DOI Scopus65 WoS60 Europe PMC56
2021 Crame, E. E., Bowen, J. M., Secombe, K. R., Coller, J. K., François, M., Leifert, W., & Wardill, H. R. (2021). Epithelial-Specific TLR4 Knockout Challenges Current Evidence of TLR4 Homeostatic Control of Gut Permeability. Inflammatory Intestinal Diseases, 6(4), 199-209.
DOI Scopus5 Europe PMC5
2021 Tam, S. Y., Coller, J. K., Hughes, P. A., Prestidge, C. A., & Bowen, J. M. (2021). Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation. Indian Journal of Gastroenterology, 40(1), 5-21.
DOI Scopus66 WoS59 Europe PMC56
2021 Korver, S., Bowen, J., Pearson, K., Gonzalez, R. J., French, N., Park, K., . . . Goldring, C. (2021). The application of cytokeratin-18 as a biomarker for drug-induced liver injury. Archives of Toxicology, 95(11), 3435-3448.
DOI Scopus43 WoS42 Europe PMC29
2021 Miranda-Silva, W., Gomes-Silva, W., Zadik, Y., Yarom, N., Al-Azri, A. R., Hong, C. H. L., . . . Elad, S. (2021). MASCC/ISOO clinical practice guidelines for the management of mucositis: sub-analysis of current interventions for the management of oral mucositis in pediatric cancer patients. Supportive Care in Cancer, 29(7), 3539-3562.
DOI Scopus57 WoS51 Europe PMC42
2021 Bruning, E. E., Coller, J. K., Wardill, H. R., & Bowen, J. M. (2021). Site-specific contribution of Toll-like receptor 4 to intestinal homeostasis and inflammatory disease. Journal of Cellular Physiology, 236(2), 877-888.
DOI Scopus38 WoS32 Europe PMC30
2021 Secombe, K. R., Ball, I. A., Shirren, J., Wignall, A. D., Keefe, D. M., & Bowen, J. M. (2021). Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant.. Breast Cancer, 28(1), 99-109.
DOI Scopus12 WoS9 Europe PMC10
2020 Chow, P. H., Bowen, J., & Yool, A. J. (2020). Combined systematic review and transcriptomic analyses of mammalian aquaporin classes 1 to 10 as biomarkers and prognostic indicators in diverse cancers. Cancers, 12(7), 1-31.
DOI Scopus26 WoS26 Europe PMC21
2020 Subramaniam, C. B., Bowen, J. M., Gladman, M. A., Lustberg, M. B., Mayo, S. J., & Wardill, H. R. (2020). The microbiota-gut-brain axis: an emerging therapeutic target in chemotherapy-induced cognitive impairment. Neuroscience and Biobehavioral Reviews, 116, 470-479.
DOI Scopus43 WoS40 Europe PMC36
2020 Wan Mohamad Zain, W. N. I. Z., Bowen, J., Bateman, E., & Keefe, D. (2020). Cytotoxic Effects of the Dual ErbB Tyrosine Kinase Inhibitor, Lapatinib, on Walker 256 Rat Breast Tumour and IEC-6 Rat Normal Small Intestinal Cell Lines.. Biomedicines, 8(1), 2-1-2-14.
DOI Scopus5 WoS4 Europe PMC5
2020 Mayo, B., Secombe, K., Wignall, A., Bateman, E., Thorpe, D., Pietra, C., . . . Bowen, J. (2020). The GLP-2 Analogue Elsiglutide Reduces Diarrhoea Caused by the Tyrosine Kinase Inhibitor Lapatinib in Rats. Cancer Chemotherapy and Pharmacology, 85(4), 793-803.
DOI Scopus26 WoS21 Europe PMC22
2020 Secombe, K. R., Van Sebille, Y. Z. A., Mayo, B. J., Coller, J. K., Gibson, R. J., & Bowen, J. M. (2020). Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome.. Integrative Cancer Therapies, 19, 1534735420928493-1-153473542092849-12.
DOI Scopus59 WoS54 Europe PMC52
2020 Chiam, K., Mayne, G. C., Wang, T., Watson, D. I., Irvine, T. S., Bright, T., . . . Hussey, D. J. (2020). Serum outperforms plasma in small extracellular vesicle microRNA biomarker studies of adenocarcinoma of the esophagus. World Journal of Gastroenterology, 26(20), 2570-2583.
DOI Scopus20 WoS19 Europe PMC20
2020 Wardill, H. R., Sonis, S. T., Blijlevens, N. M. A., Van Sebille, Y. Z. A., Ciorba, M. A., Loeffen, E. A. H., . . . Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). (2020). Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. Support Care Cancer, 28(11), 5059-5073.
DOI Scopus68 WoS61 Europe PMC49
2020 Elad, S., Cheng, K. K. F., Lalla, R. V., Yarom, N., Hong, C., Logan, R. M., . . . Zur, E. (2020). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 126(19), 4423-4431.
DOI Scopus536 WoS506 Europe PMC361
2019 Tam, S. Y. J., Coller, J. K., Wignall, A., Gibson, R. J., Khatri, A., Barbé, C., & Bowen, J. M. (2019). Intestinal accumulation of silica particles in a rat model of dextran sulfate sodium-induced colitis.. Annals of gastroenterology, 32(6), 584-592.
DOI Scopus7 WoS6 Europe PMC6
2019 Korver, S. K., Gibson, R. J., Bowen, J. M., & Coller, J. K. (2019). Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy.. Cancer Chemotherapy and Pharmacology, 83(2), 217-236.
DOI Scopus6 WoS4 Europe PMC4
2019 Secombe, K., Ball, I., Shirren, J., Wignall, A., Finnie, J., Keefe, D., . . . Bowen, J. (2019). Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model. Cancer Chemotherapy and Pharmacology, 83(3), 531-543.
DOI Scopus18 WoS12 Europe PMC14
2019 Wardill, H. R., Choo, J. M., Dmochowska, N., Mavrangelos, C., Campaniello, M. A., Bowen, J. M., . . . Hughes, P. A. (2019). Acute colitis drives tolerance by persistently altering the epithelial barrier and innate and adaptive immunity. Inflammatory Bowel Diseases, 25(7), 1196-1207.
DOI Scopus13 WoS12 Europe PMC10
2019 Al-Qadami, G., Van Sebille, Y., Le, H., & Bowen, J. (2019). Gut microbiota: implications for radiotherapy response and radiotherapy-induced mucositis. Expert Review of Gastroenterology and Hepatology, 13(5), 485-496.
DOI Scopus66 WoS59 Europe PMC54
2019 Van Sebille, Y. Z., Gibson, R. J., Wardill, H. R., Carney, T. J., & Bowen, J. M. (2019). Use of zebrafish to model chemotherapy and targeted therapy gastrointestinal toxicity.. Experimental biology and medicine (Maywood, N.J.), 244(14), 1178-1185.
DOI Scopus18 WoS17 Europe PMC13
2019 Bowen, J. M., Gibson, R. J., Coller, J. K., Blijlevens, N., Bossi, P., Al-Dasooqi, N., . . . Elad, S. (2019). Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. Supportive Care in Cancer, 27(10), 4011-4022.
DOI Scopus75 WoS60 Europe PMC46
2019 Bowen, J., Al-Dasooqi, N., Bossi, P., Wardill, H., Van Sebille, Y., Al-Azri, A., . . . Elad, S. (2019). The pathogenesis of mucositis: updated perspectives and emerging targets. Supportive Care in Cancer, 27(10), 4023-4033.
DOI Scopus144 WoS124 Europe PMC100
2019 Fakiha, K., Coller, J., Logan, R., Gibson, R., & Bowen, J. (2019). Amitriptyline prevents CPT-11-induced early-onset diarrhea and colonic apoptosis without reducing overall gastrointestinal damage in a rat model of mucositis. Supportive Care in Cancer, 27(6), 2313-2320.
DOI Scopus10 WoS9 Europe PMC10
2019 Secombe, K. R., Coller, J. K., Gibson, R. J., Wardill, H. R., & Bowen, J. M. (2019). The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy‐induced gastrointestinal toxicity. International Journal of Cancer, 144(10), 2365-2376.
DOI Scopus72 WoS66 Europe PMC59
2019 Lee, A., Bowen, J., Su, Y., Plews, E., Chung, R., Keefe, D. M., & Xian, C. (2019). Individual or combination treatments with lapatinib and paclitaxel cause potential bone loss and bone marrow adiposity in rats. Journal of Cellular Biochemistry, 120(3), 4180-4191.
DOI Scopus5 WoS5 Europe PMC6
2018 Van Sebille, Y., Gibson, R., Wardill, H., Ball, I., Keefe, D., & Bowen, J. (2018). Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer. International Journal of Cancer, 142(2), 369-380.
DOI Scopus16 WoS15 Europe PMC16
2018 Gibson, R. J., Van Sebille, Y. Z. A., Wardill, H. R., Wignall, A., Shirren, J., Ball, I. A., . . . Bowen, J. M. (2018). Selective MMP inhibition, using AZD3342, to reduce gastrointestinal toxicity and enhance chemoefficacy in a rat model. Chemotherapy, 63(5), 284-292.
DOI Scopus5 WoS5 Europe PMC2
2018 Wardill, H. R., Van Sebille, Y. Z. A., Ciorba, M. A., & Bowen, J. M. (2018). Prophylactic probiotics for cancer therapy-induced diarrhoea: A meta-analysis. Current Opinion in Supportive and Palliative Care, 12(2), 187-197.
DOI Scopus55 WoS53 Europe PMC47
2018 Stansborough, R. L., Al-Dasooqi, N., Bateman, E. H., Bowen, J. M., Keefe, D. M. K., Logan, R. M., . . . Gibson, R. J. (2018). Matrix metalloproteinase expression is altered in the small and large intestine following fractionated radiation in vivo. Supportive Care in Cancer, 26(11), 3873-3882.
DOI Scopus8 WoS8 Europe PMC6
2018 Stansborough, R. L., Bateman, E. H., Al-Dasooqi, N., Bowen, J. M., Wignall, A., Keefe, D. M., . . . Gibson, R. J. (2018). Vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFβ), angiostatin, and endostatin are increased in radiotherapy-induced gastrointestinal toxicity. International Journal of Radiation Biology, 94(7), 645-655.
DOI Scopus8 WoS6 Europe PMC6
2018 Khan, S., Wardill, H. R., & Bowen, J. M. (2018). Role of toll-like receptor 4 (TLR4)-mediated interleukin-6 (IL-6) production in chemotherapy-induced mucositis. Cancer Chemotherapy and Pharmacology, 82(1), 31-37.
DOI Scopus26 WoS22 Europe PMC20
2018 Hofma, B., Wardill, H., Mavrangelos, C., Campaniello, M., Dimasi, D., Bowen, J., . . . Hughes, P. (2018). Colonic migrating motor complexes are inhibited in acute tri-nitro benzene sulphonic acid colitis. PLoS ONE, 13(6), e0199394-1-e0199394-15.
DOI Scopus15 WoS14 Europe PMC12
2017 Van Sebille, Y., Gibson, R., Wardill, H., Secombe, K., Ball, I., Keefe, D., . . . Bowen, J. (2017). Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. International Journal of Cancer, 140(12), 2820-2829.
DOI Scopus33 WoS29 Europe PMC30
2017 Bowen, J. M. (2017). Cancer treatment-related gastrointestinal symptoms. Current Opinion in Supportive and Palliative Care, 11(2), 118-119.
DOI Scopus2 WoS1 Europe PMC1
2017 Dickenson, A. H., Farquhar-Smith, P., Bannister, K., & Bowen, J. M. (2017). Editorial introductions. CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 11(2), V-VI.
2017 Bowen, J., & Wardill, H. (2017). Advances in the understanding and management of mucositis during stem cell transplantation. Current Opinion in Supportive and Palliative Care, 11(4), 341-346.
DOI Scopus44 WoS32 Europe PMC28
2017 Campbell, J., Stephenson, M., Bateman, E., Peters, M., Keefe, D., & Bowen, J. (2017). Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics Journal, 17(1), 21-28.
DOI Scopus57 WoS49 Europe PMC39
2017 Al-Dasooqi, N., Bowen, J., Bennett, C., Finnie, J., Keefe, D., & Gibson, R. (2017). Cell adhesion molecules are altered during irinotecan-induced mucositis: a qualitative histopathological study. Supportive Care in Cancer, 25(2), 391-398.
DOI Scopus7 WoS6 Europe PMC4
2017 Mayo, B., Stringer, A., Bowen, J., Bateman, E., & Keefe, D. (2017). Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues. Cancer Chemotherapy and Pharmacology, 79(2), 233-249.
DOI Scopus19 WoS17 Europe PMC15
2017 Coller, J. K., Bowen, J. M., Ball, I. A., Wardill, H. R., Van Sebille, Y. Z. A., Stansborough, R. L., . . . Gibson, R. J. (2017). Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. Cancer Chemotherapy and Pharmacology, 79(2), 431-434.
DOI Scopus9 WoS8 Europe PMC8
2017 Wardill, H., Bowen, J., Van Sebille, Y., & Gibson, R. (2017). Routine assessment of the gut microbiome to promote preclinical research reproducibility and transparency. Gut, 66(10), 1869-1871.
DOI Scopus3 WoS3 Europe PMC2
2017 Stansborough, R., Bateman, E., Al-Dasooqi, N., Bowen, J., Keefe, D., Yeoh, A., . . . Gibson, R. (2017). Fractionated abdominal irradiation induces intestinal microvascular changes in an in vivo model of radiotherapy-induced gut toxicity. Supportive Care in Cancer, 25(6), 1973-1983.
DOI Scopus15 WoS14 Europe PMC13
2016 Wardill, H., Gibson, R., Van Sebille, Y., Secombe, K., Logan, R., & Bowen, J. (2016). A novel in vitro platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options. Experimental Biology and Medicine, 241(13), 1386-1394.
DOI Scopus8 WoS7 Europe PMC8
2016 Van Sebille, Y., Gibson, R., Wardill, H., & Bowen, J. (2016). Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Current Opinion in Supportive and Palliative Care, 10(2), 152-156.
DOI Scopus7 WoS6 Europe PMC5
2016 Wardill, H., Gibson, R., Van Sebille, Y., Secombe, K., Coller, J., White, I., . . . Bowen, J. (2016). Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms. Molecular Cancer Therapeutics, 15(6), 1376-1386.
DOI Scopus124 WoS115 Europe PMC103
2016 Wardill, H., Mander, K., Van Sebille, Y., Gibson, R., Logan, R., Bowen, J., & Sonis, S. (2016). Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction. International Journal of Cancer, 139(12), 2635-2645.
DOI Scopus144 WoS125 Europe PMC116
2016 Wardill, H., Bowen, J., Van Sebille, Y., Secombe, K., Coller, J., Ball, I., . . . Gibson, R. (2016). TLR4-dependent claudin-1 internalization and secretagogue-mediated chloride secretion regulate irinotecan-induced diarrhea. Molecular Cancer Therapeutics, 15(11), 2767-2779.
DOI Scopus45 WoS41 Europe PMC31
2016 Gibson, R., Coller, J., Wardill, H., Hutchinson, M., Smid, S., & Bowen, J. (2016). Chemotherapy-induced gut toxicity and pain: involvement of TLRs. Supportive Care in Cancer, 24(5), 2251-2258.
DOI Scopus22 WoS21 Europe PMC16
2016 Wardill, H., Logan, R., Bowen, J., Van Sebille, Y., & Gibson, R. (2016). Tight junction defects are seen in the buccal mucosa of patients receiving standard dose chemotherapy for cancer. Supportive Care in Cancer, 24(4), 1779-1788.
DOI Scopus18 WoS18 Europe PMC16
2015 Wardill, H. R., Logan, R. M., Bowen., & Gibson. (2015). Chemotherapy causes tight junction defects in the oral cavity of patients which co-incide with elevated pro inflammatory cytokines and MMPs. Australian Dent, 60(4).
2015 Campbell, J., Bateman, E., Stephenson, M., Bowen, J., Keefe, D., & Peters, M. D. (2015). Methotrexate-induced Toxicity Pharmacogenetics; an Umbrella Review of Systematic reviews and Meta-analyses. Tumor Biology: from basic science to clinical application, 78(1), 27-39.
DOI Scopus58 WoS51 Europe PMC30
2015 Campbell, J., Bateman, E., Peters, M. D., Bowen, J., Keefe, D., & Stephenson, M. (2015). Fluoropyrimidine and Platinum Toxicity Pharmacogenetics: an Umbrella Review of Systematic reviews and Meta-analyses. FutureMedicine Pharmacogenomics, 17(4), 435-451.
DOI Scopus35 WoS23 Europe PMC27
2015 Bowen, J., White, I., Smith, L., Tsykin, A., Kristaly, K., Thompson, S., . . . Keefe, D. (2015). Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study. Supportive Care in Cancer, 23(11), 3165-3172.
DOI Scopus9 WoS8 Europe PMC9
2015 Saunders, D. P., Epstein, J. B., Elad, S., Allemano, J., Bossi, P., van de Wetering, M. D., . . . Lalla, R. V. (2015). Erratum to: Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients [Support Care Cancer, DOI 10.1007/s00520-013-1871-y]. Supportive Care in Cancer, 23(2), 601-602.
DOI Scopus1 WoS2 Europe PMC1
2015 Wardill, H. R., Van Sebille, Y. Z., Bowen, J. M., & Gibson, R. J. (2015). Editorial comment: does gut-derived inflammation enhance pain signaling following chemotherapy in a Toll-like receptor 4-dependent manner?. Current Opinion in Supportive and Palliative Care, 9(2), 155-156.
DOI Scopus1 WoS1
2015 Chiam, K., Wang, T., Watson, D., Mayne, G., Irvine, T., Bright, T., . . . Hussey, D. (2015). Circulating serum exosomal miRNAs as potential biomarkers for esophageal adenocarcinoma. Journal of Gastrointestinal Surgery, 19(7), 1208-1215.
DOI Scopus131 WoS120 Europe PMC113
2015 Van Sebille, Y., Gibson, R., Wardill, H., & Bowen, J. (2015). ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: chloride secretion as a mechanistic hypothesis. Cancer Treatment Reviews, 41(7), 646-652.
DOI Scopus57 WoS52 Europe PMC39
2015 Gibson, R. J., Bowen, J. M., & Coller, J. K. (2015). What are the predictive factors in the risk and severity of chemotherapy-induced gastrointestinal toxicity?. Future Oncology, 11(17), 2367-2370.
DOI Scopus10 WoS9 Europe PMC9
2015 Wardill, H., Van Sebille, Y., Mander, K., Gibson, R., Logan, R., Bowen, J., & Sonis, S. (2015). Toll-like receptor 4 signaling: a common biological mechanism of regimen-related toxicities an emerging hypothesis for neuropathy and gastrointestinal toxicity. Cancer Treatment Reviews, 41(2), 122-128.
DOI Scopus34 WoS32 Europe PMC29
2015 Coller, J., White, I., Logan, R., Tuke, J., Richards, A., Mead, K., . . . Bowen, J. (2015). Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study. Supportive Care in Cancer, 23(5), 1233-1236.
DOI Scopus19 WoS18 Europe PMC12
2015 Lalla, R. V., Bowen, J., Barasch, A., Elting, L., Epstein, J., Keefe, D. M., . . . Elad, S. (2015). Erratum: MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy (Cancer (2014) 120 (1453-1661)). Cancer, 121(8), 1339.
DOI WoS2
2015 Al-Azri, A. R., Gibson, R. J., Bowen, J. M., Stringer, A. M., Keefe, D. M., & Logan, R. M. (2015). Involvement of matrix metalloproteinases (MMP-3 and MMP-9) in the pathogenesis of irinotecan-induced oral mucositis. Journal of Oral Pathology & Medicine, 44(6), 459-467.
DOI Scopus33 WoS31 Europe PMC24
2014 Wardill, H. R., Bowen, J. M., & Gibson, R. J. (2014). New pharmacotherapy options for chemotherapy-induced alimentary mucositis. Expert Opinion on Biological Therapy, 14(3), 347-354.
DOI Scopus17 WoS17 Europe PMC14
2014 Wardill, H., Bowen, J., Al-Dasooqi, N., Sultani, M., Bateman, E., Stansborough, R., . . . Gibson, R. (2014). Irinotecan disrupts tight junction proteins within the gut: implications for chemotherapy-induced gut toxicity. Cancer Biology and Therapy, 15(2), 236-244.
DOI Scopus74 WoS66 Europe PMC59
2014 Bowen, J., Mayo, B., Plews, E., Bateman, E., Wignall, A., Stringer, A., . . . Keefe, D. (2014). Determining the mechanisms of lapatinib-induced diarrhoea using a rat model. Cancer Chemotherapy and Pharmacology, 74(3), 617-627.
DOI Scopus27 WoS22 Europe PMC19
2014 Lalla, R. V., Bowen, J., Barasch, A., Elting, L., Epstein, J., Keefe, D. M., . . . The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). (2014). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 120(10), 1453-1461.
DOI Scopus925 WoS693 Europe PMC651
2014 Bowen, J. (2014). Development of the rat model of lapatinib-induced diarrhoea. Scientifica, 2014, 194185-1-194185-6.
DOI WoS9 Europe PMC8
2014 Wardill, H., Gibson, R., Logan, R., & Bowen, J. (2014). TLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity?. International Journal of Cancer, 135(11), 2483-2492.
DOI Scopus36 WoS33 Europe PMC25
2014 Savas, P., Robertson, A., Beatty, L., Hookings, E., Mcgee, M., Marker, J., . . . Koczwara, B. (2014). Patient preferences on the integration of complementary therapy with conventional cancer care. Asia-Pacific Journal of Clinical Oncology, 12(2), 1-8.
DOI Scopus11 WoS10 Europe PMC11
2014 Van Sebille, Y., Gibson, R., & Bowen, J. (2014). IS CROFELEMER AN EFFECTIVE INTERVENTION FOR DACOMITINIB-INDUCED GASTROINTESTINAL TOXICITY?. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 10, 208-209.
2013 Yarom, N., Ariyawardana, A., Hovan, A., Barasch, A., Jarvis, V., Jensen, S., . . . Lalla, R. (2013). Systematic review of natural agents for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21(11), 3209-3221.
DOI Scopus103 WoS84 Europe PMC72
2013 Jensen, S., Jarvis, V., Zadik, Y., Barasch, A., Ariyawardana, A., Hovan, A., . . . Elad, S. (2013). Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21(11), 3223-3232.
DOI Scopus47 WoS37 Europe PMC35
2013 McGuire, D., Fulton, J., Park, J., Brown, C., Correa, M., Eilers, J., . . . Lalla, R. (2013). Systematic review of basic oral care for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21(11), 3165-3177.
DOI Scopus202 WoS162 Europe PMC138
2013 Saunders, D., Epstein, J., Elad, S., Allemano, J., Bossi, P., van de Wetering, M., . . . Lalla, R. (2013). Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21(11), 3191-3207.
DOI Scopus134 WoS98 Europe PMC89
2013 Nicolatou-Galitis, O., Sarri, T., Bowen, J., Di Palma, M., Kouloulias, V., Niscola, P., . . . Lalla, R. (2013). Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21(11), 3179-3189.
DOI Scopus98 WoS73 Europe PMC69
2013 Bateman, E., Bowen, J., Stringer, A., Mayo, B., Plews, E., Wignall, A., . . . Keefe, D. (2013). Investigation of effect of nutritional drink on chemotherapy-induced mucosal injury and tumor growth in an established animal model. Nutrients, 5(10), 3948-3963.
DOI Scopus9 WoS10 Europe PMC9
2013 Wardill, H., & Bowen, J. (2013). Chemotherapy-induced mucosal barrier dysfunction: an updated review on the role of intestinal tight junctions. Current Opinion in Supportive and Palliative Care, 7(2), 155-161.
DOI Scopus56 WoS55 Europe PMC49
2013 Bowen, J. (2013). Mechanisms of TKI-induced diarrhea in cancer patients. Current Opinion in Supportive and Palliative Care, 7(2), 162-167.
DOI Scopus62 WoS54 Europe PMC48
2013 Al-Dasooqi, N., Sonis, S., Bowen, J., Bateman, E., Blijlevens, N., Gibson, R., . . . Lalla, R. (2013). Emerging evidence on the pathobiology of mucositis. Supportive Care in Cancer, 21(7), 2075-2083.
DOI Scopus134 WoS115 Europe PMC94
2013 Wardill, H., Bowen, J., & Gibson, R. (2013). Biomarkers of small intestinal mucosal damage induced by chemotherapy: an emerging role for the 13C sucrose breath test. The Journal of Supportive Oncology, 11(2), 61-67.
DOI Scopus14 Europe PMC9
2013 Stringer, A., Al-Dasooqi, N., Bowen, J., Tan, T., Radzuan, M., Logan, R., . . . Gibson, R. (2013). Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Supportive Care in Cancer, 21(7), 1843-1852.
DOI Scopus120 WoS114 Europe PMC105
2013 Nicolatou-Galitis, O., Sarri, T., Bowen, J., Palma, M., Kouloulias, V., Niscola, P., . . . Lalla, R. (2013). Systematic review of amifostine for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21(1), 357-364.
DOI Scopus101 WoS82 Europe PMC63
2013 Raber-Durlacher, J., von Bultzingslowen, I., Logan, R., Bowen, J., Al-Azri, A., Everaus, H., . . . Lalla, R. (2013). Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21(1), 343-355.
DOI Scopus115 WoS91 Europe PMC81
2013 Migliorati, C., Hewson, I., Lalla, R., Antunes, H., Estilo, C., Hodgson, B., . . . Elad, S. (2013). Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21(1), 333-341.
DOI Scopus201 WoS168 Europe PMC137
2013 Peterson, D., Ohrn, K., Bowen, J., Fliedner, M., Lees, J., Loprinzi, C., . . . Lalla, R. (2013). Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Supportive Care in Cancer, 21(1), 327-332.
DOI Scopus119 WoS91 Europe PMC83
2013 Gibson, R., Keefe, D., Lalla, R., Bateman, E., Blijlevens, N., Fijlstra, M., . . . Bowen, J. (2013). Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Supportive Care in Cancer, 21(1), 313-326.
DOI Scopus181 WoS161 Europe PMC132
2013 Elad, S., Bowen, J., Zadik, Y., & Lalla, R. (2013). Development of the MASCC/ISOO Clinical Practice Guidelines for Mucositis: considerations underlying the process. Supportive Care in Cancer, 21(1), 309-312.
DOI Scopus28 WoS27 Europe PMC21
2013 Bowen, J., Elad, S., Hutchins, R., & Lalla, R. (2013). Methodology for the MASCC/ISOO Mucositis Clinical Practice Guidelines Update. Supportive Care in Cancer, 21(1), 303-308.
DOI Scopus42 WoS38 Europe PMC32
2013 Al-Dasooqi, N., Sonis, S., Bowen, J., Bateman, E., Blijlevens, N., Gibson, R., . . . Lalla, R. (2013). Emerging evidence on the pathobiology of mucositis. Supportive Care in Cancer, 21(11), 3233-3241.
DOI Scopus105 WoS86 Europe PMC83
2012 Wardill, H., Bowen, J., & Gibson, R. (2012). Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal?. Cancer Chemotherapy and Pharmacology, 70(5), 627-635.
DOI Scopus36 WoS35 Europe PMC27
2012 Bowen, J., Mayo, B., Plews, E., Bateman, E., Stringer, A., Boyle, F., . . . Keefe, D. (2012). Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. Cancer Biology & Therapy, 13(13), 1269-1275.
DOI Scopus33 WoS32 Europe PMC33
2012 Sultani, M., Stringer, A., Bowen, J., & Gibson, R. (2012). Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemotherapy Research and Practice, 2012, 1-11.
DOI Europe PMC67
2012 Lalla, R., Bowen, J., & Elad, S. (2012). Mouth care protocol for oral mucositis. Journal of Oncology Pharmacy Practice, 18(1), 158.
DOI Scopus1 Europe PMC1
2011 Keefe, D., Bowen, J., Gibson, R., Tan, T., Okera, M., & Stringer, A. (2011). Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. The Oncologist, 16(4), 432-444.
DOI Scopus87 WoS69 Europe PMC51
2011 Al-Dasooqi, N., Bowen, J., Gibson, R., Logan, R., Stringer, A., & Keefe, D. (2011). Selection of housekeeping genes for gene expression studies in a rat model of irinotecan-induced mucositis. Chemotherapy, 57(1), 43-53.
DOI Scopus15 WoS16 Europe PMC14
2011 Bowen, J., Gibson, R., & Keefe, D. (2011). Animal models of mucositis: Implications for therapy. The Journal of Supportive Oncology, 9(5), 161-168.
DOI Scopus60 Europe PMC44
2011 Gibson, R., & Bowen, J. (2011). Biomarkers of regimen-related mucosal injury. Cancer Treatment Reviews, 37(6), 487-493.
DOI Scopus40 WoS35 Europe PMC34
2011 Al-Dasooqi, N., Bowen, J., Gibson, R., Logan, R., Stringer, A., & Keefe, D. (2011). Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the dark agouti rat. International Journal of Experimental Pathology, 92(5), 357-365.
DOI Scopus36 WoS32 Europe PMC28
2010 Al-Dasooqi, N., Gibson, R., Bowen, J., Logan, R., Stringer, A., & Keefe, D. (2010). Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Experimental Biology and Medicine (Maywood), 235(10), 1244-1256.
DOI Scopus59 WoS50 Europe PMC49
2010 Ong, Z., Gibson, R., Bowen, J., Stringer, A., Darby, J., Logan, R., . . . Keefe, D. (2010). Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiation Oncology, 5(22), 1-8.
DOI Scopus125 WoS114 Europe PMC100
2010 Bowen, J., Tsykin, A., Stringer, A., Logan, R., Gibson, R., & Keefe, D. (2010). Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract. Toxicology, 269(1), 1-12.
DOI Scopus11 WoS8 Europe PMC9
2010 Al-Dasooqi, N., Gibson, R., Bowen, J., Logan, R., Stringer, A., & Keefe, D. (2010). Matrix metalloproteinases and their inhibitors are altered in a time-course model of irinotecan-induced mucositis. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 25(s3), A2.
DOI
2009 Stringer, A., Gibson, R., Logan, R., Bowen, J., Yeoh, A., Laurence, J., & Keefe, D. (2009). Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemotherapy and Pharmacology, 64(1), 123-132.
DOI Scopus77 WoS73 Europe PMC69
2009 Al-Dasooqi, N., Bowen, J., Gibson, R., Sullivan, T., Lees, J., & Keefe, D. (2009). Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Investigational New Drugs, 27(2), 173-178.
DOI Scopus29 WoS22 Europe PMC17
2009 Stringer, A., Gibson, R., Bowen, J., Logan, R., Ashton, K., Yeoh, A., . . . Keefe, D. (2009). Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. International Journal of Experimental Pathology, 90(5), 489-499.
DOI Scopus136 WoS123 Europe PMC109
2009 Al-Dasooqi, N., Gibson, R., Bowen, J., & Keefe, D. (2009). HER2 targeted therapies for cancer and the gastrointestinal tract. Current Drug Targets, 10(6), 537-542.
DOI Scopus19 WoS20 Europe PMC13
2009 Al-Dasooqi, N., Gibson, R., Bowen, J., & Keefe, D. (2009). Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis?. Cancer Chemotherapy and Pharmacology, 64(1), 1-9.
DOI Scopus40 WoS40 Europe PMC29
2009 Stringer, A., Gibson, R., Logan, R., Bowen, J., Yeoh, A., Hamilton, J., & Keefe, D. (2009). Gastrointestinal Microflora and Mucins May Play a Critical Role in the Development of 5-Fluorouracil-Induced Gastrointestinal Mucositis. Experimental Biology and Medicine (Maywood), 234(4), 430-441.
DOI Scopus199 WoS183 Europe PMC154
2009 Stringer, A., Gibson, R., Bowen, J., & Keefe, D. (2009). Chemotherapy-induced modifications to gastrointestinal microflora: Evidence and implications of change. Current Drug Metabolism, 10(1), 79-83.
DOI Scopus98 WoS86 Europe PMC76
2009 Stringer, A. M., Gibson, R. J., Bowen, J. M., Logan, R. M., Al-Dasooqi, N., & Keefe, D. M. K. (2009). The importance of the gut microbiome in gastrointestinal mucositis. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 24, A237.
2009 Logan, R., Stringer, A., Bowen, J., Gibson, R., Sonis, S., & Keefe, D. (2009). Is the pathobiology of chemotherapy-induced alimentary tract mucositis inXuenced by the type of mucotoxic drug administered?. Cancer Chemotherapy and Pharmacology, 63(2), 239-251.
DOI Scopus145 WoS132 Europe PMC114
2008 Logan, R., Gibson, R., Bowen, J., Stringer, A., Sonis, S., & Keefe, D. (2008). Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemotherapy and Pharmacology, 62(1), 33-41.
DOI Scopus164 WoS150 Europe PMC145
2008 Bowen, J., & Keefe, D. (2008). New pathways for alimentary mucositis. Journal of Oncology, 2008(907892), 1-7.
DOI WoS21 Europe PMC11
2008 Stringer, A., Gibson, R., Logan, R., Bowen, J., Yeoh, A., & Keefe, D. (2008). Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biology & Therapy, 7(12), 1919-1925.
DOI Scopus178 WoS157 Europe PMC143
2008 Gibson, R., Bowen, J., & Keefe, D. (2008). Technological advances in mucositis research: New insights and new issues. Cancer Treatment Reviews, 34(5), 476-482.
DOI Scopus17 WoS15 Europe PMC8
2008 Bowen, J. (2008). Prevention and treatment of regimen-related mucosal toxicity. Recent Patents on Anti-Cancer Drug Discovery, 3(2), 68-75.
DOI Scopus3 WoS3 Europe PMC2
2008 Keefe, D., Sonis, S., & Bowen, J. (2008). Emerging drugs for chemotherapy-induced mucositis. Expert Opinion on Emerging Drugs, 13(3), 511-522.
DOI Scopus44 WoS39 Europe PMC32
2008 Logan, R., Stringer, A., Bowen, J., Gibson, R., Sonis, S., & Keefe, D. (2008). Serum levels of NF kappa B and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biology & Therapy, 7(7), 1139-1145.
DOI Scopus165 WoS142 Europe PMC125
2007 Bowen, J., Gibson, R., Stringer, A., Chan, T., Prabowo, A., Cummins, A., & Keefe, D. (2007). Role of p53 in irinotecan-induced intestinal cell death and mucosal damage. Anti-Cancer Drugs, 18(2), 197-210.
DOI Scopus24 WoS21 Europe PMC21
2007 Stringer, A., Gibson, R., Logan, R., Bowen, J., Yeoh, A., Burns, J., & Keefe, D. (2007). Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Experimental Biology and Medicine (Maywood), 232(1), 96-106.
Scopus98 WoS83 Europe PMC55
2007 Bowen, J., Stringer, A., Gibson, R., Yeoh, A., Hannam, S., & Keefe, D. (2007). VSL#3 probiotic treatment reduces chemotherapy-induced diarrhoea and weight loss. Cancer Biology & Therapy, 6(9), 1449-1454.
DOI Scopus189 WoS170 Europe PMC139
2007 Stringer, A., Gibson, R., Bowen, J., Logan, R., Yeoh, A., & Keefe, D. (2007). Chemotherapy-induced mucositis: The role of gastrointestinal microflora and mucins in the luminal environment. The Journal of Supportive Oncology, 5(6), 259-267.
Scopus72 Europe PMC48
2007 Bowen, J., Gibson, R., Cummins, A., Tyskin, A., & Keefe, D. (2007). Irinotecan changes gene expression in the small intestine of the rat with breast cancer. Cancer Chemotherapy and Pharmacology, 59(3), 337-348.
DOI Scopus38 WoS34 Europe PMC32
2007 Logan, R., Stringer, A., Bowen, J., Yeoh, A., Gibson, R., Sonis, S., & Keefe, D. (2007). The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs. Cancer Treatment Reviews, 33(5), 448-460.
DOI Scopus246 WoS223 Europe PMC193
2007 Bowen, J., Gibson, R., Tsykin, A., Stringer, A., Logan, R., & Keefe, D. (2007). Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. International Journal of Cancer, 121(8), 1847-1856.
DOI Scopus41 WoS39 Europe PMC36
2007 Yeoh, A., Gibson, R., Yeoh, E., Bowen, J., Stringer, A., Giam, K., & Keefe, D. (2007). A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis p53 nuclear factor-kappa B COX-1 and COX-2. Molecular Cancer Therapeutics, 6(8), 2319-2327.
DOI Scopus53 WoS46 Europe PMC44
2007 Gibson, R., Stringer, A., Bowen, J., Logan, R., Yeoh, A., Burns, J., . . . Keefe, D. (2007). Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biology & Therapy, 6(4), 541-547.
DOI Scopus16 WoS14 Europe PMC10
2007 Gibson, R., Bowen, J., Alvarez, E., Finnie, J., & Keefe, D. (2007). Establishment of a Single-Dose Irinotecan Model of Gastrointestinal Mucositis. Chemotherapy, 53(5), 360-369.
DOI Scopus60 WoS47 Europe PMC43
2006 Gibson, R., Cummins, A., Bowen, J., Logan, R., Healey, T., & Keefe, D. (2006). Apoptosis occurs early in the basal layer of the oral mucosa following cancer chemotherapy. Asia Pacific Journal of Clinical Oncology, 2(1), 39-49.
DOI Scopus25
2006 Yeoh, A., Gibson, R., Yeoh, E., Bowen, J., Stringer, A., Giam, K., . . . Keefe, D. (2006). Radiation therapy-induced mucositis: Relationships between fractionated radiation, NF-kappa B, COX-1, and COX-2. Cancer Treatment Reviews, 32(8), 645-651.
DOI Scopus45 WoS40 Europe PMC32
2006 Anthony, L., Bowen, J., Garden, A., Hewson, I., & Sonis, S. (2006). New thoughts on the pathobiology of regimen-related mucosal injury. Supportive Care in Cancer, 14(6), 516-518.
DOI Scopus39 WoS25 Europe PMC31
2006 Bowen, J., Gibson, R., Cummins, A., & Keefe, D. (2006). Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Supportive Care in Cancer, 14(7), 713-731.
DOI Scopus103 WoS96 Europe PMC82
2006 Bowen, J. M., Gibson, R. J., Cummins, A. G., Tyskin, A., & Keefe, D. M. K. (2006). Irinotecan-induced changes in gene expression in the small intestine of the rat with cancer. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 21, A275.
2006 Stringer, A. M., Gibson, R. J., Logan, R. M., Bowen, J. M., Yeoh, A. S. J., & Keefe, D. M. K. (2006). Chemotherapy-induced changes in mucin secretion and composition. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 21, A266.
WoS2
2006 Yeoh, A., Gibson, R., Yeoh, E., Bowen, J., Stringer, A., Giam, K., & Keefe, D. (2006). A novel animal model to investigate radiation-induced mucositis: a qualitative assessment of mucosal injury resulting from fractionated radiotherapy. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 21, A260.
2005 Bowen, J. M., Newbold, K., Blake, P., Wild, G., Egner, W., Norman, A. R., & Andreyev, H. J. N. (2005). Do serum levels of eosinophil granule-derived protein change in patients undergoing pelvic radiotherapy?. Clinical Oncology, 17(5), 382-384.
DOI Scopus6 Europe PMC4
2005 Yeoh, A., Bowen, J., Gibson, R., & Keefe, D. (2005). Nuclear factor kB (NFkB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. International Journal of Radiation Oncology Biology Physics, 63(5), 1295-1303.
DOI Scopus79 WoS70 Europe PMC65
2005 Gibson, R., Bowen, J., Cummins, A., & Keefe, D. (2005). Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. Clinical and Experimental Medicine, 4(4), 188-195.
DOI Scopus44 WoS38 Europe PMC33
2005 Gibson, R., Bowen, J., & Keefe, D. (2005). Palifermin reduces diarrhea and increases survival following Irinotecan treatment in tumor-bearing DA rats. International Journal of Cancer, 116(3), 464-470.
DOI Scopus70 WoS68 Europe PMC53
2005 Bowen, J., Gibson, R., Keefe, D., & Cummins, A. (2005). Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology, 37(1), 56-62.
DOI Scopus74 WoS71 Europe PMC58
2003 Gibson, R., Bowen, J., Inglis, M., Cummins, A., & Keefe, D. (2003). Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. Journal of Gastroenterology and Hepatology, 18(9), 1095-1100.
DOI Scopus172 WoS156 Europe PMC141

Year Citation
2021 Subramaniam, C. B., Wardill, H. R. R., Gladman, M. A., & Bowen, J. M. (2021). 5-FU induces acute neurodegeneration followed by persistent neuroinflammation: A new mechanistic hypothesis for the neurological complications of cancer therapy. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 113). WILEY.
2021 Crame, E., Wardill, H. R., Secombe, K., Coller, J., & Bowen, J. (2021). Intestinal epithelial TLR4 are crucial to chemotherapy toxicity development. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 110). WILEY.
2021 Al-Qadami, G., Bowen, J., Van Sebille, Y., Wardill, H., Secombe, K., & Le, H. (2021). Pre-treatment gut microbiome and radiotherapy response and toxicities among patients with head and neck cancer. In MASCC/ISOO Annual Meeting.
2021 Tam, J., Coller, J., Hughes, P., Prestidge, C., & Bowen, J. (2021). Investigation of TLR4 antagonists for prevention of intestinal inflammation. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 113). WILEY.
2019 Bowen, J. M., Secombe, K. R., Ball, I. A., Shirren, J., Wignall, A. D., Finnie, J. W., . . . Keefe, D. (2019). Budesonide and colesevelam reduce neratinib-induced diarrhea in a rat model. In CANCER RESEARCH Vol. 79 (pp. 2 pages). San Antonio, TX: AMER ASSOC CANCER RESEARCH.
DOI
2019 Bruning, E., Coller, J., Wardill, H., Secombe, K., & Bowen, J. (2019). Toll-like receptor 4 humanized C57BL/6 mouse intestinal permeability: A translational model for cancer treatment toxicity. In JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY Vol. 34 (pp. 166). WILEY.
2018 Wardill, H., Secombe, K., Gibson, R., Stringer, A., Al-Dasooqi, N., Mayo, B., & Bowen, J. (2018). Pre-treatment blautia abundance regulates chemo-toxicity in colorectal cancer patients: A pilot study. In NEUROGASTROENTEROLOGY AND MOTILITY Vol. 30 (pp. 1 page). WILEY.
2018 Hughes, P., Wardill, H., Choo, J., Dmochowska, N., Campaniello, M., Mavrangelos, C., . . . Rogers, G. (2018). Acute colitis chronically alters epithelial barrier and adaptive and innate immune responses to subsequent colitis re-activation independently of shifts in microbiota composition. In NEUROGASTROENTEROLOGY AND MOTILITY Vol. 30 (pp. 1 page). WILEY.
2018 Secombe, K., Bowen, J., Coller, J., Gibson, R., Stringer, A., Al-Dasooqi, N., . . . Wardill, H. R. (2018). Pre-treatment Blautia abundance regulates chemotherapy-induced gastrointestinal toxicity risk: a pilot study. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 14 (pp. 59). WILEY.
WoS2
2018 Korver, S. K., Bowen, J. M., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R., . . . Coller, J. K. (2018). Personalised supportive care for patients receiving 5-fluorouracil (5-FU): analysis of multivariate SNP risk prediction for GI toxicity. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 14 (pp. 58-59). WILEY.
2015 Vanhoecke, B., Mayo, B., Wignall, A., Ziegler, V., Stringer, A., Bateman, E., . . . Keefe, D. (2015). Irinotecan induces DNA damage in the oral cavitiy of the Dark Agouti rats without visual signs of lesions. In Supportive Care in Cancer Vol. 23 (pp. S115). Copenhagen, Denmark: Springer Verlag (Germany).
DOI
2015 Wan Mohamad Zain, W., Bowen, J., Bateman, E., & Keefe, D. (2015). Investigation of lapatinib-induced diarrhea in a tumour-bearing rat model. In Supportive Care in Cancer Vol. 23 (pp. S387). Copenhagen, Denmark: Springer Verlag (Germany).
DOI
2015 Mayo, B., Stringer, A., Lucchesi, C., Bowen, J., Bateman, E., Wignall, A., . . . Keefe, D. (2015). Microbial alterations and toll-like receptor expression play a role in the improvement of irinotecan-induced mucositis after treatment with the new selective GLP-2 receptor agonist, Elsiglutide. In Supportive Care in Cancer Vol. 23 (pp. S111). Copenhagen, Denmark: Springer Verlag (Germany).
DOI
2013 Al-Azri, A. S., Logan, R., Gibson, R., Keefe, D., stringer, A., & Bowen, J. (2013). The role of matrix metalloproteinases and tissue inhibitors of metalloproteinase in irinotecan induced-chemotherapy. In Supportive Care in Cancer. Berlin Genrmany: Springer Verlag (Germany).
2013 Abstracts of the MASCC/ISOO (Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology) International Symposium on Supportive Care in Cancer. June 27-29, 2013. Berlin, Germany. (2013). In Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer Vol. 21 Suppl 1 (pp. S2-301). Germany: Springer Science and Business Media LLC.
DOI Europe PMC2
2012 Abstracts of the 2012 International MASCC/ISOO (Multiple Association of Supportive Care in Cancer/International Society for Oral Oncology) Symposium. New York City, New York, USA. June 28-30, 2012. (2012). In Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer Vol. 20 Suppl 1 (pp. 1-283). Germany: Springer Science and Business Media LLC.
DOI Europe PMC2
2010 Al-Dasooqi, N., Bowen, J., Gibson, R., Logan, R., Stringer, A., & Keefe, D. (2010). Irinotecan-induced mucositis encompasses changes in intestinal and colonic cell kinetics and this is associated with altered extracellular matrix component expression. In Abstracts of the 2010 International MASCC/ISOO Symposium Vol. 25 (pp. 0 pages). Vancouver, Canada: Springer-Verlag.
DOI
2010 Al-Dasooqi, N., Gibson, R., Bowen, J., Logan, R., Stringer, A., & Keefe, D. (2010). Matrix metalloproteinases play a pivotal role in the development of alimentary tract mucositis. In Sydney Cancer Conference (pp. 0 pages). The University of Sydney, NSW, Australia.
2009 Stringer, A., Gibson, R., Yeoh, A., Bowen, J., Logan, R., & Keefe, D. (2009). CHEMOTHERAPY-INDUCED DIARRHOEA IS ASSOCIATED WITH A MODIFIED MICROBIOME IN GI CANCER PATIENTS. In ANNALS OF ONCOLOGY Vol. 20 (pp. 73). Barcelona, SPAIN: OXFORD UNIV PRESS.
2007 Logan, R., Gibson, R., Stringer, A., Bowen, J., Sonis, S., & Keefe, D. (2007). Serum levels of nuclear factor-κB and tumour necrosis factor following irinotecan administration in the Dark Agouti rat. In ORAL ONCOLOGY (pp. 211). Amsterdam, NETHERLANDS: ELSEVIER SCIENCE BV.
2007 Logan, R., Gibson, R., Stringer, A., Bowen, J., Sonis, S., & Keefe, D. (2007). Nuclear factor-KB and cyclooxygenase-2 expression in the oral mucosa following cancer chemotherapy. In ORAL ONCOLOGY (pp. 171). Amsterdam, NETHERLANDS: ELSEVIER SCIENCE BV.

Year Citation
2022 Subramaniam, C., Wardill, H. R., Gladman, M., & Bowen, J. (2022). High fibre diet significantly reduces astrocyte abundance in a mouse model of 5-FU induced neuroinflammation. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2021 Secombe, K. R., Ball, I. A., Wignall, A. D., Bateman, E., Diala, I., Lalani, A. S., & Bowen, J. M. (2021). Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats.. Poster session presented at the meeting of CANCER RESEARCH. Philadelphia, PA: AMER ASSOC CANCER RESEARCH.
2021 Al-Qadami, G., Verma, G., Van Sebille, Y., Le, H., Hewson, I., & Bowen, J. (2021). Antibiotic-induced depletion of gut microbiota reduces injury area and duration of radiation-induced oral mucositis in rats. Poster session presented at the meeting of Abstracts of the MASCC/ISOO Annual Meeting 2021, as published in Supportive Care in Cancer. virtual online: Springer.
DOI
2020 Al-Qadami, G., Van Sebille, Y., Hien, L., Hewson, I., & Bowen, J. (2020). Antibiotic-induced depletion of gut microbiota: Impact on radiation-induced oral mucositis in rats. Poster session presented at the meeting of NEUROGASTROENTEROLOGY AND MOTILITY. WILEY.
2019 Al-Qadami, G., Van Sebille, Y., Le, H., Hewson, I., & Bowen, J. (2019). Antibiotic-induced depletion of gut microbiota: Impact on radiation-induced oral mucositis in rats. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2019 Coller, J. K., Korver, S. K., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R. M., . . . Bowen, J. M. (2019). Predictors of severe gastrointestinal toxicity risk in patients treated with 5-fluorouracil-based chemotherapy: A validation study. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2017 Secombe, K. R., Ball, I. A., Shirren, J., Wignall, A. D., Wardill, H. R., Van Sebille, Y. Z. A., & Bowen, J. M. (2017). Budesonide Reduces Neratinib-Induced Gastrointestinal Injury and Diarrhoea in Rats. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
WoS2
2017 Bowen, J., Ball, I., Thompson, S., Irvine, T., Chiam, K., Hussey, D., . . . Keefe, D. (2017). Identification of Inflammatory Markers of Chemoradiotherapy-Induced Gastrointestinal Toxicity in Oesophageal Cancer. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2017 Korver, S. K., Ball, I. A., Gibson, R. J., Logan, R. M., Karapetis, C. S., Keefe, D. M., . . . Coller, J. K. (2017). The Effect of Immune Genetic Variants on Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2017 Korver, S. K., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R. M., Richards, A., . . . Coller, J. K. (2017). Interleukin-1 Beta (<i>IL1B</i>) Genetic Variability is Predictive of Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2017 Wardill, H., Bowen, J., Dmochowska, N., Campaniello, M., Mavrangelos, C., Holloway, R., . . . Hughes, P. (2017). Faecal supernatants from diarrhoea predominant Irritable Bowel Syndrome (IBS) patients disrupt colonic epithelial barrier function and directly activate colo-rectal afferent nerves. Poster session presented at the meeting of Abstracts of the NeuroGASTRO 2017 Congress, as published in Neurogastroenterology and Motility. Cork, Ireland: Wiley.
DOI
2017 Wardill, H. R., Dmochowska, N., Campaniello, M. A., Mavrangelos, C., Bowen, J. M., Andrews, J. M., . . . Hughes, P. A. (2017). Fecal supernatants from active ulcerative colitis patients impair colonic epithelial barrier integrity and activate pelvic mucosal extrinsic afferent nerves. Poster session presented at the meeting of FASEB Journal. Chicago, IL: Federation of American Societies for Experimental Biology.
2014 Mayo, B., Stringer, A., Bateman, E., Bowen, J., Wignall, A., Wozniak, B., . . . Keefe, D. (2014). Apoptosis, proliferation and inflammation are improved after treatment with the new selective glp-2 receptor agonist, elsiglutide, in a rat model of irinotecan-induced mucositis. Poster session presented at the meeting of Asia-Pacific Journal Of Clinical Oncology. Melbourne, Vic.: Wiley.
DOI
2014 Mayo, B., Stringer, A., Bateman, E., Bowen, J., Pietra, C., Cantoreggi, S., & Keefe, D. (2014). Apoptosis, proliferation and inflammation are improved after treatment with the new selective GLP-2 receptor agonist, Elsiglutide, in a rat model of irinotecan-induced mucositis. Poster session presented at the meeting of Supportive Care in Cancer. Miami, USA: Springer Verlag (Germany).
2013 Bateman, E., Wilson, C., Keefe, C., Bowen, J., Wignall, A., Plews, E., & Keefe, D. (2013). Fractionated radiotherapy in a rat model causes dose-dependent changes in collagen deposition, and expression of transforming growth factor β1, Smad3 and smooth muscle actin α1. Poster session presented at the meeting of Supportive Care in Cancer. Berlin, Germany: Springer Verlag (Germany).
DOI
2013 Wan Mohamad Zain, W., Bowen, J., Bateman, E., & Keefe, D. (2013). Development of a walker 256-TC tumour-bearing rat model to study lapatinib-induced mucosal injury. Poster session presented at the meeting of Supportive Care in Cancer. Berlin, Germany: Springer Verlag (Germany).
DOI
2013 Radzuan, M., Bateman, E., Bowen, J., Keefe, D., & Stringer, A. (2013). Intestinal Lactobacillus spp. increase following radiotherapy in rats: an unusual finding. Poster session presented at the meeting of Supportive Care in Cancer. Berlin, Germany: Springer Verlag (Germany).
2013 Bowen, J., White, I., Tuke, J., Logan, R., Richards, A., Mead, K., . . . Coller, J. (2013). IMMUNE GENETIC VARIABILITY IS ASSOCIATED WITH RISK OF SEVERE GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH FLUOROURACIL. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL.
2011 Bateman, E., Bowen, J., Mayo, B., Plews, E., Darby, J., Stringer, A., . . . Keefe, D. (2011). Further characterisation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor-induced diarrhoea. Poster session presented at the meeting of Abstracts of the 2011 International MASCC/ISOO Symposium, as published in Supportive Care in Cancer. Athens: Springer-Verlag.
DOI
2009 Stringer, A. M., Gibson, R. J., Bowen, J. M., Logan, R. M., Al-Dasooqi, N., & Keefe, D. M. K. (2009). Chemotherapy-induced diarrhoea is associated with a modified microbiome in cancer patients. Poster session presented at the meeting of Abstracts of the Australia & New Zealand Medical & Surgical Gastrointestinal Week 2009, as published in Journal of Gastroenterology and Hepatology. Sydney, N.S.W.: Wiley-Blackwell.
DOI

Year Citation
2016 Wardill, H. (2016). Toll-like receptor 4-dependent barrier dysfunction and its impact on irinotecan-induced gut toxicity and pain. (PhD Thesis).
Funding

Prof Bowen’s research program has been funded by NHMRC, MRFF, Cancer Council SA, SA Cancer Research Collaborative, Cure Cancer Australia, Australian Dental Research Foundation, the Ray and Shirl Norman Cancer Research Trust, the Royal Adelaide Hospital Research Committee, Flinders University, The Hospital Research Foundation and University of Adelaide. With her co-investigators, funding received has totalled over $5 Million dollars. Industry has been a major funder and continues to be an area of increasing linkage. Current and previous industry partners include Kallyope (PI), GlaxoSmithKline (CI), Helsinn Healthcare (CI), Pfizer Pharmaceuticals (PI), Puma Biotechnology (PI), Zhendong, Pharmaceuticals (AI), CSIRO (CI), AstraZeneca (CI), Danone (CI) and Pantheryx (CI).        

Teaching

In 2011, Prof Bowen was appointed to lecturer in Physiology, University of Adelaide, promoted to senior lecturer in 2015, and then associate professor in 2017, which has provided opportunities to teach and train the next generation of researchers. She teaches within the B.HlthMedSc program, particularly involved in delivery of gastrointestinal physiology content. She was Deputy Chair of the Faculty Gender Equity and Diversity committee (2017-2019) and implements inclusive practices for courses she teaches.

Prof Bowen is the Faculty Honours Coordinator and a Senior Postgraduate Coordinator for the School of Biomedicine. In 2024 she also took on the role of Associate Dean, Gender Equity, Diversity and Inclusion. Through these roles she is able to provide leadership in training the next generation of health and medical science researchers.

Date Role Research Topic Program Degree Type Student Load Student Name
2025 Principal Supervisor Investigating the effect of fibre supplementation on improving chemotherapy toxicity outcomes Doctor of Philosophy Doctorate Full Time Miss Linh Hang To
2025 Co-Supervisor Dietary interventions for protection from chemotherapy-induced bone loss Doctor of Philosophy Doctorate Full Time Miss Linjie Zhang
2025 External Supervisor - Doctor of Philosophy Doctorate Full Time Miss Nicole Chan
2025 Co-Supervisor Dietary interventions for protection from chemotherapy-induced bone loss Doctor of Philosophy Doctorate Full Time Miss Linjie Zhang
2025 Principal Supervisor Investigating the effect of fibre supplementation on improving chemotherapy toxicity outcomes Doctor of Philosophy Doctorate Full Time Miss Linh Hang To
2024 Co-Supervisor Investigating the effect of dietary intake on bone loss and fracture risk in women with breast cancer Doctor of Philosophy Doctorate Full Time Miss Negin Amin
2024 Co-Supervisor The Transcranial Magnetic stimulation for Chemotherapy-induced pain Study (TMaC Study) Master of Philosophy (Medical Science) Master Full Time Mrs Eva Kate Moore
2024 Co-Supervisor Gut microbiota and endocannabinoid system interactions in cancer: understanding mechanisms to inform supportive oncology interventions Doctor of Philosophy Doctorate Full Time Miss Katrina Cao
2024 External Supervisor - - Master Full Time Mr Alex Hunter
2024 Co-Supervisor Investigating the effect of dietary intake on bone loss and fracture risk in women with breast cancer Doctor of Philosophy Doctorate Full Time Miss Negin Amin
2024 Co-Supervisor The Transcranial Magnetic stimulation for Chemotherapy-induced pain Study (TMaC Study) - Master Full Time Mrs Eva Kate Moore
2024 Co-Supervisor Gut microbiota and endocannabinoid system interactions in cancer: understanding mechanisms to inform supportive oncology interventions Doctor of Philosophy Doctorate Full Time Miss Katrina Cao
2023 Co-Supervisor Neuropsychological complications of chemotherapy and the involvement of the endocannabinoid system. Doctor of Philosophy Doctorate Full Time Miss Olivia Marie Bellas
2023 Co-Supervisor Neuropsychological complications of chemotherapy and the involvement of the endocannabinoid system. Doctor of Philosophy Doctorate Full Time Miss Olivia Marie Bellas
2022 Principal Supervisor Identifying biomarkers of cachexia and mucositis Doctor of Philosophy Doctorate Part Time Mrs Claire Patricia Vieyra
2022 Principal Supervisor Exploring the effect of diet and gut microbiota on breast cancer using the Dark Agouti Mammary Adenocarcinoma (DAMA) model. Doctor of Philosophy Doctorate Full Time Ms Ifeoma Julieth Dikeocha
2022 Principal Supervisor Identifying biomarkers of cachexia and mucositis Doctor of Philosophy Doctorate Full Time Mrs Claire Patricia Vieyra
2022 Principal Supervisor Exploring the effect of diet and gut microbiota on breast cancer using the Dark Agouti Mammary Adenocarcinoma (DAMA) model. Doctor of Philosophy Doctorate Full Time Ms Ifeoma Julieth Dikeocha

Date Role Research Topic Program Degree Type Student Load Student Name
2022 - 2025 Co-Supervisor Exploring the mechanisms of and protective interventions for skeletal
effects induced by breast cancer treatments		 Doctor of Philosophy Doctorate Full Time Miss Micaela Jocelyn Quinn
2021 - 2023 Principal Supervisor An Investigation of Biological Processes Underlying Neratinib-induced Gut Injury Master of Philosophy (Medical Science) Master Full Time Mr Phu Minh Triet Nguyen
2021 - 2025 Co-Supervisor Assessing Chemotherapy-Induced Bone Loss and a Novel Dietary Approach to Mitigate Bone Loss Doctor of Philosophy Doctorate Full Time Mr Bailey Michael Deverell
2019 - 2023 Principal Supervisor The Role of TLR4 in Chemotherapy-Induced Toxicity, Immunity and Tumour Growth Doctor of Philosophy Doctorate Full Time Mrs Elise Ellen Crame
2019 - 2023 Principal Supervisor The Microbiota Gut Brain Axis in the Neuropsychological Complications of Chemotherapy Treatment Doctor of Philosophy Doctorate Full Time Miss Courtney Brooke Cross
2019 - 2021 Principal Supervisor Exploring the Role of the Gut Microbiome in Toxicity and Response to Radiotherapy for Head and Neck Cancer Doctor of Philosophy Doctorate Full Time Mrs Ghanyah Hamid Hussein Al-Qadami
2018 - 2022 Principal Supervisor Exploring the Effects of Toll-Like Receptor 4 Antagonism on Gastrointestinal Mucositis and Tumour Activity Doctor of Philosophy Doctorate Full Time Miss Shu Yie Janine Tam
2017 - 2021 Principal Supervisor Exploration of the gut microbiome as a predictive factor for cancer treatment-induced gastrointestinal toxicity Doctor of Philosophy Doctorate Full Time Miss Kate Rebecca Secombe
2016 - 2020 Co-Supervisor Identifying potential genetic, phenotypic and epigenetic predictive markers in the Toll-like receptor/Interleukin-1 domain innate immune signalling pathway for severe gastrointestinal toxicity risk following 5-Fluorouracil-based therapy Doctor of Philosophy Doctorate Full Time Miss Samantha Kaitlyn Korver
2016 - 2022 Co-Supervisor Role of Aquaporin 1 in Diseases and Drug Discovery Doctor of Philosophy Doctorate Full Time Mr Pak Hin Chow
2014 - 2017 Principal Supervisor Characterisation and Treatment of Pan-Human Epidermal Receptor Tyrosine Kinase Inhibitor-Induced Gastrointestinal Toxicity Doctor of Philosophy Doctorate Full Time Bella Van Sebille
2013 - 2016 Co-Supervisor Toll-Like Receptor 4-Dependent Barrier Dysfunction and its Impact on Irinotecan-Induced Gut Toxicity and Pain Doctor of Philosophy Doctorate Full Time APrf Hannah Rose Wardill
2011 - 2016 Co-Supervisor In vitro and in vivo Models to assess the mechanism of Lapatinib - Induced Diarrhoea Doctor of Philosophy Doctorate Full Time Mrs Wan Nor I'zzah Wan Mohamad Zain
2010 - 2015 Principal Supervisor A Study Linking Toll-like Receptors and Irinotecan-induced Gastrointestinal Mucositis Doctor of Philosophy Doctorate Full Time Mrs Khloud Ghazi Fakiha
2008 - 2012 Co-Supervisor Chemotherapy-Induced Mucositis: The Role of Matrix Metalloproteinases and the Extracellular Matrix Doctor of Philosophy Doctorate Full Time Miss Noor Al-Dasooqi

Date Role Board name Institution name Country
2020 - ongoing Secretary MASCC Executive Board MASCC United States
2018 - ongoing Board Member Multinational Association of Supportive Care in Cancer MASCC United States
2014 - 2017 Director Australian Society for Medical Research Australian Society for Medical Research Australia

Date Role Committee Institution Country
2014 - ongoing Member Multinational Association of Supportive Care in Cancer Governance Committee - -
2008 - ongoing Member South Australian ASMR committee - -

Date Role Editorial Board Name Institution Country
2017 - ongoing Editor Inflammopharmacology Springer Switzerland
2015 - 2018 Editor Gastroenterology Research and Practice Hindawi Publishing Corporation Egypt

Connect With Me

External Profiles

Other Links